amoxicillin-potassium-clavulanate-combination and Bile-Duct-Diseases

Amoxicillin/clavulanate is associated with liver injury, mostly of a cholestatic pattern. While outcomes are usually benign, progression to cirrhosis and death has been reported. The role of immunosuppressive therapy for patients with a protracted course is unclear. We report the case of an elderly patient who developed prolonged cholestasis secondary to amoxicillin/clavulanate. Vanishing bile duct syndrome was confirmed by sequential liver biopsies. The patient responded to prednisone treatment, but could not be weaned off corticosteroids, even when azathioprine was added. Complete withdrawal of both prednisone and azathioprine was possible by using mycophenolate mofetil, an inosine monophosphate dehydrogenase inhibitor. Sustained remission has been maintained for more than 3 years with low-dose mycophenolate mofetil.

Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bile Duct Diseases; Humans; Immunosuppressive Agents; Male; Mycophenolic Acid

Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bile Duct Diseases; Child; Cholestasis, Intrahepatic; Humans; Male; Treatment Outcome; Ursodeoxycholic Acid

Hepatotoxity associated with amoxicillin/clavulanic acid is usually a self-limited disease with complete recovery. We report a rapidly progressing liver disease with ductopenia and portal fibrosis in a 3-year-old boy treated with Augmentin.

Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Child, Preschool; Cholestasis; Drug Eruptions; Drug Therapy, Combination; Humans; Jaundice; Liver; Liver Cirrhosis; Male